Congress caps inhaler costs at $15 for asthma, COPD patients nationwide
H.R. 5278 — Affordable Inhalers and Nebulizers Act of 2025 · Filed by Kweisi Mfume (D-MD) · 13 cosponsors · Introduced Sep 10, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill caps patient cost-sharing for prescription inhalers and nebulizers used to treat asthma and COPD at $15 per 30-day supply across private insurance, Medicare Part B, Medicare Part D, and creates a federal payment program for uninsured individuals. The bill applies to all maintenance, reliever, rescue, and equipment-related inhaler products with medically accepted indications, and ensures these costs count toward deductibles and out-of-pocket maximums.
Why we flagged it
The bill's operative mechanism is a price ceiling ($15 per 30-day supply) and deductible waiver for a specific class of essential medications. This is direct cost regulation, not a subsidy or tax provision.
What the text implies
- The $15 cap applies uniformly across all inhalers regardless of acquisition cost or therapeutic class, potentially creating supply-chain pressure on lower-cost generics and incentivizing manufacturers to bundle or reformulate products to avoid the cap.
- Medicare Part D cost-sharing caps may shift financial burden from beneficiaries to plan sponsors and the federal government, potentially affecting premium structures for all Part D enrollees in subsequent years.
The full analysis lists 5 implications of this text.
Who stands to gain
patients with asthma and COPD (primary beneficiaries); uninsured individuals with respiratory disease; Medicare beneficiaries